Bone Biologics Corp 8-K

What Happened On January 8, 2026, Bone Biologics Corporation announced and furnished a press release under Item 7.01 (Regulation FD Disclosure) summarizing the company's corporate, scientific and operational milestones achieved in 2025 and outlining its strategic outlook for 2026. The press release is included as Exhibit 99.1 to the Form 8‑K filed that day.

Key Details

• Date of disclosure: January 8, 2026 (press release furnished under Item 7.01, Regulation FD Disclosure).
• Exhibit filed: Press Release dated January 8, 2026 (Exhibit 99.1) was furnished with the Form 8‑K.
• The filing reports corporate, scientific and operational milestones from 2025 and sets out the company’s strategic plans for 2026.
• This 8‑K does not include earnings, financial results, executive changes (CEO/CFO), mergers or acquisitions—only the press release disclosure and interactive data exhibit were furnished.

Why It Matters The disclosure provides investors with a public update on Bone Biologics’ progress in 2025 and management’s priorities for 2026, which can help assess the company’s operational momentum and near‑term plans. Because the information was furnished under Regulation FD, it is intended as broad public disclosure rather than confidential correspondence with specific investors. Note that no new financial results or personnel changes were reported in this filing.